WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H576084
CAS#: 503068-34-6 (free base)
Description: Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist. It selectively induces cAMP accumulation in CHO cells expressing the β2-AR over the β1- and β3-ARs (EC50s = 0.4, 398, and 794 nM for the human receptors, respectively). Vilanterol inhibits contractions induced by electrical stimulation in isolated superfused guinea pig trachea strips. It inhibits bronchospasms induced by histamine. Formulations containing vilanterol, in combination with fluticasone, have been used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Hodoodo Cat#: H576084
Name: Vilanterol
CAS#: 503068-34-6 (free base)
Chemical Formula: C24H33Cl2NO5
Exact Mass: 485.17
Molecular Weight: 486.430
Elemental Analysis: C, 59.26; H, 6.84; Cl, 14.58; N, 2.88; O, 16.45
Related CAS #: 503070-58-4 (trifenatate) 503068-34-6 (free base) 503070-59-5 (cinnamate)
Synonym: GW 642444; GW642444; GW-642444; Vilanterol
IUPAC/Chemical Name: (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
InChi Key: DAFYYTQWSAWIGS-DEOSSOPVSA-N
InChi Code: InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
SMILES Code: ClC1=C(COCCOCCCCCCNC[C@H](O)C2=CC=C(O)C(CO)=C2)C(Cl)=CC=C1
Appearance: A solution in ethanol
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, DMF, Ethanol
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
Soluble in DMSO | 0.0 | 100.00 |
The following data is based on the product molecular weight 486.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Cazzola, M., Calzetta, L., and Matera, M.G. β2-adrenoceptor agonists: Current and future direction. Br. J. Pharmacol. 163(1), 4-17 (2011).
2. Mach, R.H., Nader, M.A., Ehrenkaufer, R.L., et al. Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography. Synapse 24(4), 322-333 (1996).
3. Procopiou, P.A., Barrett, V.J., Bevan, N.J., et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: An antedrug approach. J. Med. Chem. 53(11), 4522-4530 (2010).
4. De Coster, D.A., and Jones, M. Tailoring of corticosteroids in COPD management. Curr.Respir.Care Rep. 3, 121-132 (2014).
5. Cohen, J.S., Miles, M.C., Donohue, J.F., et al. Dual therapy strategies for COPD: The scientific rationale for LAMA + LABA. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 785-797 (2016).